A 52-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: GLAXOSMITHKLINE RESEARCH DEVELOPMENT LTD
- Phase: III
- Execution start: 21/07/2021
- End of execution: 30/09/2023
- IP: CONCEPTION MORALES GARCIA